T2 Biosystems (NASDAQ:TTOO) is a commercial-stage in vitro diagnostics company that develops and markets innovative medical diagnostic products based on its proprietary T2 Magnetic Resonance (T2MR) technology. The company’s core mission is to provide healthcare professionals with rapid, sensitive, and accurate diagnostic solutions that accelerate the detection of serious infectious diseases directly from whole blood. T2 Biosystems’ technology leverages targeted magnetic resonance to identify pathogenic nucleic acids in patient samples without the need for lengthy culture steps, enabling clinicians to make informed treatment decisions more quickly.
The company’s flagship product, the T2Dx® Instrument, serves as an automated platform for running a range of molecular diagnostic assays. The T2Candida® and T2Bacteria® Panels are designed to detect multiple clinically significant pathogens associated with bloodstream infections, including Candida species and bacterial species such as Staphylococcus aureus and Escherichia coli. Building on these core offerings, T2 Biosystems has advanced pipeline assays targeting antimicrobial resistance markers (T2Resistance™ Panel) and viral pathogens, positioning the company to address emerging infectious disease threats and hospital-acquired infections.
Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems was co‐founded by Carl Balch, John McDonough, and other life science entrepreneurs to harness novel magnetic resonance applications for clinical microbiology. The company completed its initial public offering in 2017 and trades on the NASDAQ under the ticker symbol TTOO. Under the leadership of CEO John McDonough, T2 Biosystems has expanded its operational footprint, strengthened its R&D capabilities, and built strategic partnerships with academic institutions, contract research organizations, and commercial distributors.
With regulatory clearances in the United States and CE marking in Europe, T2 Biosystems serves hospitals, reference laboratories, and health systems across North America and select international markets. The company continues to invest in clinical studies and collaborations aimed at validating its technology in additional disease areas, while pursuing regulatory approvals that support broader adoption of its rapid diagnostic solutions. Through ongoing innovation and partnerships, T2 Biosystems seeks to enhance patient outcomes, reduce healthcare costs, and address unmet needs in the early detection of life-threatening infections.
